Highlights Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
5.2 ^USD	-4.41%		-4.76%	+6.34%

13/05	Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024
13/05	Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M	14/05	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting	09/05	CI
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	25/04	MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24/04	CI
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06/03	CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	01/03	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03	CI
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03	CI
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise	27/02	MT
Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization	20/02	CI
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine	24/01	DJ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2	24/01	CI
Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis	12/12	CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Reports Q3 Revenue $6.2M, vs. Street Est of $3.17M	15/11	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy	29/23/29	CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q2 Revenue $3.9M, vs. Street Est of $1.6M	08/23/08	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
Capricor Therapeutics Announces Appointment of Philip J. Gotwals to Its Board of Directors	24/23/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Highlights

Filters